Literature DB >> 26301078

Concomitant use of two or more antipsychotic drugs is common in Sweden.

Annica Bergendal1, Helena Schiöler2, Björn Wettermark3, Karin Sparring Björkstén4.   

Abstract

OBJECTIVES: To assess the prevalence of concomitant use of two or more antipsychotic drugs and other psychotropic drugs in the Swedish population.
METHODS: Data for this observational cohort study were collected from the Swedish Prescribed Drug Register including all dispensed drugs to the entire Swedish population (9.4 million inhabitants). We identified all individuals with at least one dispensed prescription of antipsychotic drug during January to June 2008. After 12 months, a second exposure period was chosen. Individuals who were dispensed two or more antipsychotic drugs in both periods were considered long-time users of antipsychotic polypharmacy.
RESULTS: In 2008, 1.5% of the Swedish population was dispensed antipsychotic drugs, the majority (75%) using only one antipsychotic drug. Out of individuals who were dispensed 2 or more antipsychotic drugs during the first period, 62% also was also dispensed at least 2 antipsychotic drugs during the second period. A total of 665 different unique combinations were used in 2008. Individuals prescribed two or more antipsychotic drugs during both periods were more often dispensed anxiolytics and sedatives than those who were dispensed only one antipsychotic drug. Elderly were dispensed antipsychotic drugs much more often than younger persons.
CONCLUSIONS: In Sweden, 25% of patients dispensed antipsychotic drugs receive a combination of two or more antipsychotic drugs. Individuals who are dispensed antipsychotic polypharmacy are more often dispensed anxiolytics and sedatives than those prescribed only one antipsychotic drug. Long-term observational studies are needed to assess the efficacy and safety of such combinations.

Entities:  

Keywords:  antipsychotic agents; drug polytherapy; drug utilization; polypharmacy; psychotic disorders; schizophrenia

Year:  2015        PMID: 26301078      PMCID: PMC4535048          DOI: 10.1177/2045125315588647

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  26 in total

Review 1.  Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.

Authors:  Pasquale De Fazio; Paolo Girardi; Giuseppe Maina; Massimo Carlo Mauri; Mauro Mauri; Palmiero Monteleone; Giulia Ida Perini; Giulio Perugi; Alessandro Rossi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  To what extent does the indicator "concurrent use of three or more psychotropic drugs" capture use of potentially inappropriate psychotropics among the elderly?

Authors:  Eva Lesén; Max Petzold; Karolina Andersson; Anders Carlsten
Journal:  Eur J Clin Pharmacol       Date:  2009-02-12       Impact factor: 2.953

Review 4.  The Nordic countries as a cohort for pharmacoepidemiological research.

Authors:  Kari Furu; Björn Wettermark; Morten Andersen; Jaana E Martikainen; Anna Birna Almarsdottir; Henrik Toft Sørensen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-04       Impact factor: 4.080

5.  Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Authors:  Rahul Ganguly; Jeffrey A Kotzan; L Stephen Miller; Klugh Kennedy; Bradley C Martin
Journal:  J Clin Psychiatry       Date:  2004-10       Impact factor: 4.384

6.  Multiple antipsychotic medication prescribing patterns.

Authors:  Jennifer E Schumacher; Eugene H Makela; Holly R Griffin
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

Review 7.  Polypharmacy with second-generation antipsychotics: a review of evidence.

Authors:  Anand K Pandurangi; Alican Dalkilic
Journal:  J Psychiatr Pract       Date:  2008-11       Impact factor: 1.325

8.  The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people.

Authors:  Syed Imran Haider; Kristina Johnell; Gunilla Ringbäck Weitoft; Mats Thorslund; Johan Fastbom
Journal:  J Am Geriatr Soc       Date:  2008-11-14       Impact factor: 5.562

9.  Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Authors:  Julie A Kreyenbuhl; Marcia Valenstein; John F McCarthy; Dara Ganoczy; Frederic C Blow
Journal:  Psychiatr Serv       Date:  2007-04       Impact factor: 3.084

10.  Adding or switching antipsychotic medications in treatment-refractory schizophrenia.

Authors:  Julie Kreyenbuhl; Steven C Marcus; Joyce C West; Joshua Wilk; Mark Olfson
Journal:  Psychiatr Serv       Date:  2007-07       Impact factor: 3.084

View more
  4 in total

1.  Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study.

Authors:  Erica M Brostedt; Mussie Msghina; Marie Persson; Björn Wettermark
Journal:  BMC Psychiatry       Date:  2017-12-29       Impact factor: 3.630

2.  Association between antipsychotic drug dose and length of clinical notes: a proxy of disease severity?

Authors:  Freja Karuna Hemmingsen Sørup; Søren Brunak; Robert Eriksson
Journal:  BMC Med Res Methodol       Date:  2020-05-07       Impact factor: 4.615

3.  COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review.

Authors:  Marc De Hert; Victor Mazereel; Marc Stroobants; Livia De Picker; Kristof Van Assche; Johan Detraux
Journal:  Front Psychiatry       Date:  2022-01-13       Impact factor: 4.157

4.  Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review.

Authors:  Rafaella Georgiou; Demetris Lamnisos; Konstantinos Giannakou
Journal:  Front Psychiatry       Date:  2021-12-28       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.